IPAC-RS Projects for Orally Inhaled and Nasal Drug Products (OINDP)
CURRENT
IPAC-RS 2011 - 2013 Strategic Plan
Points to Consider for a P2 for an Orally Inhaled or Nasal Drug Product
Cascade Impaction
Delivered Dose Uniformity
Device Design Dissolution Rate Testing of Orally Inhaled Products Leachables and Extractables
International Industry Coordinating Group
Materials for OINDP
Patient Adherence with Inhalation Therapies
QbD for Analytical Methods
Risk Management
Supplier Quality Control
| 
Text Size (
